Global OTC Artificial Tears Market Size and Forecast, 2025–2033
The global OTC artificial tears market is projected to expand from US$ 4.70 billion in 2024 to US$ 7.22 billion by 2033, registering a CAGR of 4.88% during 2025–2033. The market’s upward trajectory is supported by the increasing prevalence of dry eye syndrome, rising awareness of eye health, expanding retail accessibility, and continuous innovation in ophthalmic formulations.
Artificial tears are widely used ophthalmic solutions designed to lubricate and hydrate the eyes, offering relief from dryness, irritation, burning, and discomfort. These symptoms are increasingly common due to prolonged screen exposure, aging populations, environmental pollution, contact lens use, and certain medical conditions.
The growing accessibility of over-the-counter (OTC) products through pharmacies, supermarkets, online platforms, airports, shopping malls, and healthcare facilities has significantly strengthened market penetration globally.
Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=otc-artificial-tears-market-key-players-analysis-p.php
Market Overview
Dry eye syndrome (DES) has become one of the most prevalent ocular disorders worldwide. Urban lifestyles characterized by digital device dependency, air-conditioned environments, and reduced blinking rates are contributing to increased cases of eye dryness and fatigue.
Artificial tears mimic natural tear film properties, restoring moisture balance and stabilizing the ocular surface. Modern formulations include preservative-free options for sensitive users and long-acting lubricants that enhance tear film stability.
Growing consumer education campaigns and ophthalmologist recommendations further drive adoption. As preventive eye care becomes a priority, artificial tears are increasingly integrated into daily wellness routines.
The OTC nature of these products ensures broad accessibility, enabling consumers to self-manage mild to moderate dry eye symptoms without prescription requirements.
Key Growth Drivers
Rising Prevalence of Dry Eye Syndrome
The increasing global burden of dry eye syndrome remains the primary growth catalyst. Aging populations are more susceptible to tear production decline, while environmental stressors and lifestyle habits further exacerbate symptoms.
Extended screen time in professional and educational settings has intensified eye strain and dryness across younger demographics as well. Consequently, demand for safe, easily accessible lubricating eye drops continues to grow.
Companies such as Alcon and Bausch Health Companies Inc. are continuously innovating advanced tear film stabilization solutions tailored to varying severity levels of dry eye.
Expanding Retail Access and OTC Availability
The availability of artificial tears across pharmacies, hypermarkets, convenience stores, and online channels has enhanced consumer access. Digital pharmacies and e-commerce platforms provide additional convenience and price transparency.
Global healthcare companies like Johnson & Johnson leverage strong retail networks and brand recognition to expand product distribution worldwide.
The growing presence of artificial tear products in public access locations such as airports and shopping centers further supports impulse purchases and accessibility.
Technological Innovation and Advanced Formulations
Innovation in nanotechnology, lipid-based formulations, and preservative-free packaging is enhancing product performance and patient comfort.
In April 2023, Sun Pharmaceutical Industries Ltd. launched CEQUA® in India, a nanomicellar-based ophthalmic treatment for dry eye disease with inflammation, reflecting advancements in drug delivery systems.
Similarly, in February 2025, Rohto Pharmaceutical Co., Ltd. strengthened its presence in Türkiye through a strategic partnership, expanding access to innovative eye health products.
These developments underscore the importance of R&D in improving tear film retention time, reducing irritation, and enhancing patient compliance.
Company Analysis
AbbVie Inc.
AbbVie is a specialty biopharmaceutical company with a strong eye-care portfolio. The company operates globally through extensive manufacturing facilities and distribution channels. Its ophthalmic solutions are backed by robust R&D capabilities, ensuring high efficacy and safety standards.
AbbVie’s global reach and partnerships with healthcare providers strengthen its presence in the OTC artificial tears market.
Akorn Inc.
Akorn focuses on sterile and non-sterile ophthalmic formulations, offering both branded and OTC products. Its diversified dosage forms and strong distribution network across hospitals and retail pharmacies contribute to steady market presence.
Alcon
Alcon is a leading global eye-care company specializing in surgical products and contact lenses. Its artificial tear solutions benefit from clinical research collaborations and advanced ophthalmic innovation pipelines.
Bausch Health Companies Inc.
Bausch Health operates across dermatology, gastroenterology, neurology, and eye health. Its OTC artificial tears portfolio is supported by global distribution capabilities and manufacturing facilities in multiple regions.
Johnson & Johnson
Johnson & Johnson’s vision care division plays a key role in OTC artificial tear distribution. Its strong brand equity and healthcare infrastructure allow widespread global accessibility.
SWOT Insights
Abbott Laboratories Inc. – Strength
Abbott Laboratories benefits from strong brand credibility and global ophthalmic expertise. Its established R&D capabilities support preservative-free and clinically validated formulations, enhancing consumer trust and medical endorsement.
Cipla Limited – Strength
Cipla Limited leverages affordability and strong presence in emerging markets. Its focus on accessible pricing and regulatory-compliant manufacturing enables penetration into cost-sensitive regions while maintaining product quality.
Recent Developments
In May 2025, Nicox S.A. reported positive results from its Phase 3b exploratory trial for NCX 470, reflecting ongoing innovation in ophthalmic solutions.
In September 2024, URSAPHARM Arzneimittel GmbH expanded its eyelid care portfolio with EvoTears® OMEGA, addressing blepharitis and tear film instability.
These developments demonstrate active investment in eye health innovation across both prescription and OTC segments.
Sustainability Initiatives
Novartis AG
Novartis aims for carbon neutrality by 2025 and net-zero emissions by 2040. Sustainability initiatives include renewable energy sourcing, waste reduction, and water conservation, aligning healthcare innovation with environmental responsibility.
CooperVision Inc.
CooperVision has committed to a net-zero plastic footprint and promotes circular economy principles in contact lens packaging and manufacturing. Its sustainability efforts reinforce eco-conscious eye care solutions.
Market Segmentation
By Product Type
· Preservative-Free Artificial Tears
· Preserved Artificial Tears
· Lipid-Based Formulations
· Gel Drops and Ointments
By Distribution Channel
· Retail Pharmacies
· Hospital Pharmacies
· Online Pharmacies
· Supermarkets & Hypermarkets
By Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Competitive Landscape
The global OTC artificial tears market features strong competition among multinational pharmaceutical and ophthalmology companies. Market players focus on:
· Advanced drug delivery systems
· Preservative-free multi-dose packaging
· Strategic partnerships
· Geographic expansion
· Sustainability initiatives
Companies covered in comprehensive five-viewpoint analysis include:
· AbbVie Inc
· Akorn Inc.
· Alcon
· Bausch Health Companies Inc.
· Johnson & Johnson
· Nicox S.A.
· Novartis AG
· Santen Pharmaceutical Co. Ltd.
· Sun Pharmaceutical Industries Ltd.
· Abbott Laboratories Inc.
· Cipla Limited
· Rohto Pharmaceutical Co., Ltd.
· CooperVision Inc.
· Prestige Consumer Healthcare Inc.
· AFT Pharmaceuticals Ltd.
· URSAPHARM Arzneimittel GmbH
· OCuSOFT Inc.
· OASIS Medical Inc.
· Laboratoires Théa S.A.S.
· GBN Pharmaceuticals
Final Thoughts
The global OTC artificial tears market is on a robust growth trajectory, projected to reach US$ 7.22 billion by 2033 at a CAGR of 4.88%. Rising dry eye prevalence, growing screen exposure, increased health awareness, and enhanced OTC accessibility are key market accelerators.
Technological innovation, preservative-free advancements, and sustainability initiatives will further shape the competitive landscape. As preventive eye care becomes a cornerstone of global health strategies, OTC artificial tears are poised to remain indispensable components of everyday ocular wellness routines worldwide.
